Johnson & Johnson’s first-quarter earnings reveal a solid performance, with record sales and earnings, beating expectations. Management’s upbeat tone highlights the strength of new product launches and international growth potential. While the stock may face some pressure due to generic competition and OTC production delays impacting short-term results, the overall positive momentum and promising pipeline indicate a positive longer-term outlook.

1